The role of DNA methylation in the development and progression of lung adenocarcinoma

Disease Markers

Volumn 23, Issue 1-2, 2007, Pages 5-30

  Kerr, Keith M ^a   Galler, Janice S ^b   Hagen, Jeffrey A ^b   Laird, Peter W ^b   Laird Offringa, Ite A ^b,c  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

AAH; Adenocarcinoma; BAC; CpG island; DNA methylation; Hypermethylation; Hypomethylation

Indexed keywords

APC PROTEIN; CADHERIN; CALCITONIN; CYCLIN D2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; DEATH ASSOCIATED PROTEIN KINASE; ESTROGEN RECEPTOR; FIBRILLIN 2; GAP JUNCTION PROTEIN; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MYOSIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE C; PROTEIN KINASE LKB1; PROTEIN MLH1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR; SEROTONIN 1B RECEPTOR; SUPPRESSOR OF CYTOKINE SIGNALING 3; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 5; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR RUNX3; UNINDEXED DRUG; UVOMORULIN;

ANTIGEN EXPRESSION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CIGARETTE SMOKING; CPG ISLAND; DISEASE MARKER; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE LOCUS; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CARCINOGENESIS; LUNG LAVAGE; LYMPH NODE METASTASIS; METASTASIS; MICROMETASTASIS; MISMATCH REPAIR; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

EID: 33847373449     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/985474     Document Type: Review

References (250)

1. ACS, Cancer facts & figures-2005. 2005, American Cancer Society: Atlanta.
2. L.A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller, L.X. Clegg, A. Mariotto, E.J. Feuer and B.K. Edwards, eds, SEER Cancer Statistics Review, 1973-1996, National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/1975 2001/, 2004.
3. A.J. Sasco, M.B. Secretan and K. Sraif, Tobacco smoking and cancer: a brief review of recent epidemiological evidence, Lung Cancer 45(Suppl 2) (2004), S3-S9.
4. National Center for Health Statistics, Health, United States, 2004. 2004: Hyattsville, MD.
5. J.O. Ebbert, P. Yang, C.M. Vachon, R.A. Vierkant, J.R. Cerhan, A.R. Folsom and T.A. Sellers, Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women, J. Clin. Oncol. 21 (2003), 921-926.
6. W.D. Travis, Pathology of lung cancer, Clin. Chest Med. 23 (2002), 65-81.
7. W.D. Travis, L.B. Travis and S.S. Devesa, Lung Cancer, Cancer 75 (1995), 191-202.
8. K.-Y. Chen, C.-H. Chang, C.-J. Yu, S.-H. Kuo and P.-C. Yang, Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma, Cancer 103 (2005), 2566-2574.
9. I. Yoshimi, A. Ohshima, W. Ajiki, H. Tsukuma and T. Sobue, A comparison of trends in the incidence rate of lung cancer by histological type in the Osaka Cancer Registry, Japan, and in the Surveillance, Epidemiology and End Results Program, USA, Jpn. J. Clin. Oncol. 33 (2003), 98-104.
10. M.J. Thun, C.A. Lally, J.T. Flannery, E.E. Clle, W.D. Flanders and C.W.J. Heath, Cigarette smoking and changes in the histopathology of lung cancer, J. Natl. Cancer Inst. 89 (1997), 1580-1586.
11. S.D. Stellman, J.E. Muscat, D. Hoffmann and E.L. Wynder, Impact of filter cigarette smoking on lung cancer histology, Prev. Med. 26 (1997), 451-456.
12. N.S. Liu, M.R. Spitz, B.L. Kemp, C. Cooksley, F.V. Fossela, J.S. Lee, W.K. Hong and F.R. Khuri, Adenocarcinoma of the lung in young patients; the M.D. Anderson experience, Cancer 88 (2000), 1837-1841.
13. Y.C. Chen, J.H. Chen, K. Richard, P.Y. Chen and D.C. Christiani, Lung adenocarcinoma and human papillomavirus infection, Cancer 101 (2004), 1428-1236.
14. P.A. Jones and P.W. Laird, Cancer epigenetics comes of age, Nature Genet. 21 (1999), 163-167.
15. P.W. Laird, Oncogenic mechanisms mediated by DNA methylation, Molec. Med. Today 3 (1997), 223-229.
16. M. Esteller, Epigenetics provides a new generation of oncogenes and tumour-suppressor genes, Br J Cancer 94 (2006), 179-183.
17. S.B. Baylin, M. Esteller, M.R. Rountree, K.E. Bachman, K. Schuebel and J.G. Herman, Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer, Hum. Mol. Genet. 10 (2001), 687-692.
18. A.P. Bird and A.P. Wolffe, Methylation-induced repression - belts, braces and chromatin, Cell 99 (1999), 451-454.
19. M.R. Rountree, K.E. Bachman, J.G. Herman and S.B. Baylin, DNA methylation, chromatin inheritance, and cancer, Oncogene 20 (2001), 3156-3165.
20. P.A. Jones and S.B. Baylin, The fundamental role of epigenetic events in cancer, Nature Reviews Genetics 3 (2002), 415-428.
21. P.W. Laird, The Power and the Promise of DNA Methylation Markers, Nature Reviews Cancer 3 (2003), 253-266.
22. A.P. Bird, CpG-rich islands and the function of DNA methylation, Nature 321 (1986), 209-213.
23. F. Larsen, G. Gundersen, R. Lopez and H. Prydz, CpG islands as gene markers in the human genome, Genomics 13 (1992), 1095-1107.
24. D. Takai and P.A. Jones, Comprehensive analysis of CpG islands in the human chromosomes 21 and 22, Proc. Natl. Acad. Sci. USA 99 (2002), 3740-3745.
25. A.P. Feinberg, R. Ohlsson and S. Henikoff, The epigenetic progenitor origin of human cancer, Nat Rev Genet 7 (2006), 21-33.
26. P.A. Wade, Methyl CpG binding proteins: coupling chromatin architecture to gene regulation, Oncogene 20 (2001), 3166-3173.
27. J.P. Issa, CpG-island methylation in aging and cancer, Curr. Top. Microbiol. Immunol. 249 (2000), 101-118.
28. J.C. Costello, M.C. Fruhwald, D.J. Smiraglia, L.J. Rush, G.P. Robertson, X. Gao, F.A. Wright, J.D. Feramisco, P. Peltomaki, J.C. Lang, D.E. Schuller, L. Yu, C.D. Bloomfield, M.A. Caligiuri, A. Yates, R. Nishikawa, H.J.S. Huang, N.J. Petrelli, X. Zhang, M.S. O'Dorisio, W.A. Held, W.K. Cavenee and C. Plass, Aberrant CpG-island methylation has nonrandom and tumor-type-specific patterns, Nature Genet. 25 (2000), 132-138.
29. M. Esteller, P.G. Corn, S.B. Baylin and J.G. Herman, A gene hypermethylation profile of human cancer, Cancer Res. 61 (2001), 3225-3229.
30. J.A. Tsou, J.A. Hagen, C.L. Carpenter and I.A. Laird-Offringa, DNA methylation analysis: a powerful new tool for lung cancer diagnosis, Oncogene 21 (2002), 5450-5461.
31. S.A. Belinsky, Gene-promoter hypermethylation as a biomarker in lung cancer, Nature Reviews Cancer 4 (2004), 1-11.
32. W. Digel and M. Lubbert, DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results, Crit Rev Oncol Hematol 55 (2005), 1-11.
33. E.S. Lander, L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, J. Baldwin, K. Devon, K. Dewar, M. Doyle, W. FitzHugh, R. Funke and D. Gage, Initial sequencing and analysis of the human genome, Nature 409 (2001), 860-921.
34. A.P. Feinberg, The epigenetics of cancer etiology, Semin. Cancer Biol. 14 (2004), 427-432.
35. I.M. Wilson, J.J. Davies, M. Weber, C.J. Brown, C.E. Alvarez, C. MacAulay, D. Schubeler and W.L. Lam, Epigenomics: mapping the methylome, Cell Cycle 5 (2006), 155-158.
36. A.K. Virmani, J.A. Tsou, K.D. Siegmund, L. Shen, T.I. Long, P.W. Laird, A.F. Gazdar and I.A. Laird-Offringa, Hierarchical clustering of lung cancer cell lines using DNA methylation markers, Cancer Epid. Biom. Prev. 11 (2002), 291-297.
37. S. Toyooka, K.O. Toyooka, R. Maruyama, A.K. Virmani, L. Girard, K. Miyajima, K. Harada, Y. Ariyoshi, T. Takahashi, K. Sugio, E. Brambilla, M. Gilcrease, J.D. Minna and A.F. Gazdar, DNA methylation profiles of lung tumors, Mol. Cancer Therap. 1 (2001), 61-67.
38. S. Toyooka, M. Suzuki, T. Tsuda, K.O. Toyooka, R. Maruyama, K. Tsukuda, Y. Fukuyama, T. Iizasa, T. Fujisawa, N. Shimizu, J.D. Minna and A.F. Gazdar, Dose effect of smoking on aberrant methylation in non-small cell lung cancers, Int. J. Cancer 110 (2004), 462-464.
39. S. Toyooka, R. Maruyama, K.O. Toyooka, D. McLerran, Z. Feng, Y. Fukuyama, A.K. Virmani, S. Zochbauer-Muller, K. Tsukuda, K. Sugio, N. Shimizu, K. Shimizu, H. Lee, C.-Y. Chen, K.M. Fong, M. Gilcrease, J.A. Roth, J.D. Minna and A.F. Gazdar, Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer, Int. J. Cancer 103 (2003), 153-160.
40. S. Zochbauer-Muller, J.D. Minna and A.F. Gazdar, Aberrant DNA methylation in lung cancer: biological and clinical implications, Oncologist 7 (2002), 451-457.
41. J.M. Nigro, K.R. Cho, E.R. Fearon, S.E. Kern, J.M. Ruppert, J.D. Oliner, K.W. Kinzler and B. Vogelstein, Scrambled exons, Cell 64 (1991), 607-613.
42. E.R. Fearon and B. Vogelstein, Agenetic model for colorectal tumorigenesis, Cell 61 (1990), 759-767.
43. M. Guo, M.G. House, C. Hooker, Y. Han, E. Heath, E. Gabrielson, S.C. Yang, S.B. Baylin, J.G. Herman and M.V. Brock, Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res 10 (2004), 5131-5136.
44. B.J. Braakhuis, M.P. Tabor, J.A. Kummer, C.R. Leemans and R.H. Brakenhoff, A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications, Cancer Res. 63 (2003), 1727-1230.
45. E. Giovannucci and S. Ogino, DNA methylation, field effects, and colorectal cancer, J Natl Cancer Inst 97 (2005), 1317-1319.
46. D.P. Slaughter, H.W. Southwick and W. Smejkal, Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin, Cancer 6 (1953), 963-968.
47. D. Schottenfeld, Epidemiology of lung cancer, in: Lung cancer: principles and practice, H.I. Pass, J.B. Mitchell, D.H. Johnson and A.T. Turrisi, eds, Lippincott-Raven Publishers: Philadelphia, 1996, pp. 305-321.
48. M.F. Fraga, E. Ballestar, M.F. Paz, S. Ropero, F. Setien, M.L. Ballestar, D. Heine-Suner, J.C. Cigudosa, M. Urioste, J. Benitez, M. Boix-Chornet, A. Sanchez-Aguilera, C. Ling, E. Carlsson, P. Poulsen, A. Vaag, Z. Stephan, T.D. Spector, Y.Z. Wu, C. Plass and M. Esteller, Epigenetic differences arise during the lifetime of monozygotic twins, Proc Natl Acad Sci USA 102 (2005), 10604-10609.
49. L. Shen, Y. Kondo, G.L. Rosner, L. Xiao, N.S. Hernandez, J. Vilaythong, P.S. Houlihan, R.S. Krouse, A.R. Prasad, J.G. Einspahr, J. Buckmeier, D.S. Alberts, S.R. Hamilton and J.P. Issa, MGMT promoter methylation and field defect in sporadic colorectal cancer, J Natl Cancer Inst 97 (2005), 1330-1338.
50. J.A. Tsou, L.Y.C. Shen, K.D. Siegmund, T.I. Long, P.W. Laird, C. Seneviratne, M.N. Koss, H.I. Pass, J.A. Hagen and I.A. Laird-Offringa, Distinct DNA methylation patterns in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung, Lung Cancer 47 (2005), 193-204.
51. K.M. Kerr, Pulmonary preinvasive neoplasia, J. Clin. Pathol. 54 (2001), 257-271.
52. Y. Shimosato, T. Kodama and T. Kameya, Morphogenesis of peripheral type adenocarcinoma of the lung., in Morphogenesis of lung cancer, Y. Shimosato, M.R. Melamed and P. Nettesheim, Editors. (1982), CRCPress: Boca Raton. 65-90.
53. F.A. Carey, Pulmonary adenocarcinoma: classification and molecular biology, J. Pathol. 184 (1998), 229-230.
54. W.H. Westra, Early glandular neoplasia of the lung, Respir. Res. 1 (2000), 163-169.
55. W.H. Westra, R.J. Slebos, G.J. Offerhaus, S.N. Goodman, S.G. Evers, T.W. Kensler, F.B. Askin, S. Rodenhuis and R.H. Hruban, K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung, Cancer 72 (1993), 432-438.
56. W.H. Westra, I.O. Baas, R.H. Hruban, F.B. Askin, K. Wilson, G.J. Offerhaus and R.J. Slebos, K-ras oncogene activation in atypical alveolar hyperplasias of the human lung, Cancer Res. 56 (1996), 2224-2228.
57. S. Niho, T. Yokose, K. Suzuki, T. Kodama, Y. Nishiwaki and K. Mukai, Monoclonality of atypical adenomatous hyperplasia of the lung, Am. J. Pathol. 154 (1999), 249-254.
58. A. Berns, Stem cells for lung cancer? Cell 121 (2005), 811-813.
59. C.F. Kim, E.L. Jackson, A.E. Woolfenden, S. Lawrence, I. Babar, S. Vogel, D. Crowley, R.T. Bronson and T. Jacks, Identification of bronchioalveolar stem cells in normal lung and lung cancer, Cell 121 (2005), 823-835.
60. W.D. Travis, T.V. Colby and B. Corrin, Histological Typing of Lung Cancer and Pleural Tumors, WHO International Histological Classification of Tumors, (3rd edition), Springer: Berlin, 1999, 29-.
61. W.D. Travis, K. Garg, W.A. Franklin, Wistuba, II, B. Sabloff, M. Noguchi, R. Kakinuma, M. Zakowski, M. Ginsberg, R. Padera, F. Jacobson, B.E. Johnson, F. Hirsch, E. Brambilla, D.B. Flieder, K.R. Geisinger, F. Thunnisen, K. Kerr, D. Yankelevitz, T.J. Franks, J.R. Galvin, D.W. Henderson, A.G. Nicholson, P.S. Hasleton, V. Roggli, M.S. Tsao, F. Cappuzzo and M. Vazquez, Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma, J Clin Oncol 23 (2005), 3279-3287.
62. K. Nakanishi, T. Kawai, F. Kumaki, S. Hirot, M. Mukai and E. Ikeda, Expression of human telomerase RNA component and telomerase reverse transcriptase mRNA in atypical adenomatous hyperplasia of the lung, Hum. Pathol. 33 (2002), 697-702.
63. C.F. Mountain, Revisions in the international system for staging lung cancer, Chest 111 (1997), 1710-1717.
64. C.F. Mountain and C.M. Dresler, Regional lymph node classification for lung cancer staging, Chest 111 (1997), 1718-1723.
65. H.T. Bjornsson, H. Cui, D. Gius, M.D. Fallin and A.P. Feinberg, The new field of epigenomics: implications for cancer and other common disease research, Cold Spring Harb Symp Quant Biol 69 (2004), 447-456.
66. P. Wolf, Y.C. Hu, K. Doffek, D. Sidransky and S.A. Ahrendt, O6-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer, Cancer Res. 61 (2001), 8113-8117.
67. H.S. Hsu, C.K. Wen, Y.A. Tang, R.K. Lin, W.Y. Li, W.H. Hsu and Y.C. ang, Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer, Clin Cancer Res. 11 (2005), 5410-5416.
68. M.F. Paz, S. Avila, M.F. Fraga, M. Pollan, G. Capella, M.A. Peinado, M. Sanchez-Cespedes, J.G. Herman and M. Esteller, Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors, Cancer Res. 62 (2002), 4519-4524.
69. H. Shen, L. Wang, M.R. Spitz, W.K. Hong, L. Mao and Q. Wei, A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer, Cancer Res. 62 (2002), 4992-4995.
70. S.J. Lee, H.S. Jeon, J.S. Jang, S.H. Park, G.Y. Lee, B.H. Lee, C.H. Kim, Y.M. Kang, W.K. Lee, S. Kam, R.W. Park, I.S. Kim, Y.L. Cho, T.H. Jung and J.Y. Park, DNMT3B polymorphisms and risk of primary lung cancer, Carcinogenesis 26 (2005), 403-409.
71. T.S. Lin, H. Lee, R.A. Chen, M.L. Ho, C.Y. Lin, Y.H. Chen, Y.Y. Tsai, M.C. Chou and Y.W. Cheng, An association of DNMT3b protein expression with P16INK4a promoter hypermethylation in non-smoking female lung cancer with human papillomavirus infection, Cancer Lett 226 (2005), 77-84.
72. F.D. Gilliland, H.J. Harms, R.E. Crowell, Y.F. Li, R. Willink and S.A. Belinsky, Glutathione S-transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16(INK4a) and O(6)-methylguanine-DNA methyltransferase in sputum, Cancer Res. 62 (2002), 2248-2252.
73. B. Vogelstein and K.W. Kinzler, Cancer genes and the pathways they control, Nat Med 10 (2004), 789-799.
74. W.A. Franklin, A.F. Gazdar, J. Haney, Wistuba, II, F.G. La Rosa, T. Kennedy, D.M. Ritchey and Y.E. Miller, Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis, J Clin Invest 100 (1997), 2133-2137.
75. Wistuba, II, C. Behrens, A.K. Virmani, G. Mele, S. Milchgrub, L. Girard, J.W. Fondon, 3rd, H.R. Garner, B. McKay, F. Latif, M.I. Lerman, S. Lam, A.F. Gazdar and J.D. Minna, High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints, Cancer Res. 60 (2000), 1949-1960.
76. E.R. Zabarovsky, M.I. Lerman and J.D. Minna, Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers, Oncogene 21 (2002), 6915-6935.
77. I.W. Park, Wistuba, II, A. Maitra, S. Milchgrub, A.K. Virmani, J.D. Minna and A.F. Gazdar, Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer, J Natl Cancer Inst 91 (1999), 1863-1868.
78. U. Grepmeier, W. Dietmaier, J. Merk, P.J. Wild, E.C. Obermann, M. Pfeifer, F. Hofstaedter, A. Hartmann and M. Woenckhaus, Deletions at chromosome 2q and 12p are early and frequent molecular alterations in bronchial epithelium and NSCLC of long-term smokers, Int J Oncol 27 (2005), 481-488.
79. M. Sanchez-Cespedes, S.A. Ahrendt, S. Piantadosi, R. Rosell, M. Monzo, L. Wu, W.H. Westra, S.C. Yang, J. Jen and D. Sidransky, Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers, Cancer Res. 61 (2001), 1309-1313.
80. Wistuba, II, L. Mao and A.F. Gazdar, Smoking molecular damage in bronchial epithelium, Oncogene 21 (2002), 7298-7306.
81. T.M. Holm, L. Jackson-Grusby, T. Brambrink, Y. Yamada, W.M. Rideout, 3rd and R. Jaenisch, Global loss of imprinting leads to widespread tumorigenesis in adult mice, Cancer Cell 8 (2005), 275-285.
82. R. Kaplan, K. Luettich, A. Heguy, N.R. Hackett, B.G. Harvey and R.G. Crystal, Monoallelic up-regulation of the imprinted H19 gene in airway epithelium of phenotypically normal cigarette smokers, Cancer Res. 63 (2003), 1475-1482.
83. M. Kondo, H. Suzuki, R. Ueda, H. Osada, K. Takagi, T. Takahashi and T. Takahashi, Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers, Oncogene 10 (1995), 1193-1198.
84. M. Kohda, H. Hoshiya, M. Katoh, I. Tanaka, R. Masuda, T. Takemura, M. Fujiwara and M. Oshimura, Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma, Mol Carcinog 31 (2001), 184-191.
85. J.P. Issa, P.M. Vertino, C.D. Boehm, I.F. Newsham and S.B. Baylin, Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis, Proc Natl Acad Sci USA 93 (1996), 11757-11762.
86. C.J. Piyathilake, A.R. Frost, W.C. Bell, D. Oelschlager, H. Weiss, G.L. Johanning, A. Niveleau, D.C. Heimburger and W.E. Grizzle, Altered global methylation of DNA: en epigenetic difference in susceptibility for lung cancer is associated with its progression, Hum. Path. 32 (2001), 856-862.
87. B.N. Trinh, T.I. Long, A.E. Nickel, D. Shibata and P.W. Laird, DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair, Mol Cell Biol 22 (2002), 2906-2917.
88. F. Gaudet, J.G. Hodgson, A. Eden, L. Jackson-Grusby, J. Dausman, J.W. Gray, H. Leonhardt and R. Jaenisch, Induction of tumors in mice by genomic hypomethylation, Science 300 (2003), 489-492.
89. S.A. Belinsky, W.A. Palmisano, F.D. Gilliland, L.A. Crooks, K.K. Divine, S.A. Winters, M.J. Grimes, H.J. Harms, C.S. Tellez, T.M. Smith, P.P. Moots, J.F. Lechner, C.A. Stidley and R.E. Crowell, Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers, Cancer Res. 62 (2002), 2370-2377.
90. K. Fujiwara, N. Fujimoto, M. Tabata, K. Nishii, K. Matsuo, K. Hotta, T. Kozuki, M. Aoe, K. Kiura, H. Ueoka and M. Tanimoto, Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer, Clin Cancer Res. 11 (2005), 1219-1225.
91. S.A. Belinsky, K.J. Nikula, W.A. Palmisano, R. Michels, G. Saccomanno, E. BGabrielson, S.B. Baylin and J.G. Herman, Aberrant methylation of p16 INK4a is an early event in lung cancer and potential biomarker for early diagnosis, Proc. Natl. Acad. Sci. USA 95 (1998), 11891-11896.
92. M. Kersting, C. Friedl, A. Kraus, M. Behn, W. Pankow and M. Schuermann, Differential frequencies of p16INK4a promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers, J. Clin. Oncol. 18 (2000), 3221-3229.
93. W.A. Palmisano, K.K. Divine, G. Saccomanno, F.D. Gilliland, S.B. Baylin, J.G. Herman and S.A. Belinsky, Predicting lung cancer by detecting aberrant promoter methylation in sputum, Cancer Res. 60 (2000), 5954-5958.
94. S.A. Belinsky, K.C. Liechty, F.D. Gentry, H.J. Wolf, J. Rogers, K. Vu, J. Haney, T.C. Kennedy, F.R. Hirsch, Y. Miller, W.A. Franklin, J.G. Herman, S.B. Baylin, P.A. Bunn and T. Byers, Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort, Cancer Res. 66 (2006), 3338-3344.
95. D.H. Kim, J.S. Kim, Y.I. Ji, Y.M. Shim, H. Kim, J. Han and J. Park, Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer, Cancer Res. 63 (2003), 3743-3746.
96. C.J. Marsit, D.H. Kim, M. Liu, P.W. Hinds, J.K. Wiencke, H.H. Nelson and K.T. Kelsey, Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence, Int J Cancer 114 (2005), 219-223.
97. J. Roche and H.A. Drabkin, The role of semaphorins in lung cancer, Clin Lung Cancer 3 (2001), 145-150.
98. T. Kuroki, F. Trapasso, S. Yendamuri, A. Matsuyama, H. Alder, N.N. Williams, L.R. Kaiser and C.M. Croce, Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer, Cancer Res. 63 (2003), 3352-3355.
99. S.A. Belinsky, D.M. Klinge, C.A. Stidley, J.P. Issa, J.G. Herman, T.H. March and S.B. Baylin, Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer, Cancer Res. 63 (2003), 7089-7093.
100. S.A. Belinsky, S.S. Snow, K.J. Nikula, G.L. Finch, C.S. Tellez and W.A. Palmisano, Aberrant CpG island methylation of the p16(INK4a) and estrogen receptor genes in rat lung tumors induced by particulate carcinogens, Carcinogenesis 23 (2002), 335-339.
101. V. Dasari, M. Gallup, H. Lemjabbar, I. Maltseva and N. McNamara, Epithelial-mesenchymal Transition in Lung Cancer: Is Tobacco the "Smoking Gun"? Am J Respir Cell Mol Biol (2006).
102. J. Mazieres, B. He, L. You, Z. Xu and D.M. Jablons, Wnt signaling in lung cancer, Cancer Lett 222 (2005), 1-10.
103. J. Behrens and B. Lustig, The Wnt connection to tumorigenesis, Int J Dev Biol 48 (2004), 477-487.
104. N. Ahuja and J.P. Issa, Aging, methylation and cancer, Histol Histopathol 15 (2000), 835-842.
105. T. Waki, G. Tamura, M. Sato and T. Motoyama, Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples, Oncogene 22 (2003), 4128-4133.
106. A.J. Simpson, O.L. Caballero, A. Jungbluth, Y.T. Chen and L.J. Old, Cancer/testis antigens, gametogenesis and cancer, Nat Rev Cancer 5 (2005), 615-625.
107. K. Tajima, Y. Obata, H. Tamaki, M. Yoshida, Y.T. Chen, M.J. Scanlan, L.J. Old, H. Kuwano, T. Takahashi, T. Takahashi and T. Mitsudomi, Expression of cancer/testis (CT) antigens in lung cancer, Lung Cancer 42 (2003), 23-33.
108. S.J. Jang, J.-C. Soria, L. Wang, K.A. Hassan, R.C. Morice, G.L. Walsh, W.K. Hong and L. Mao, Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis, Cancer Res. 61 (2001), 7959-7963.
109. K.A. Olaussen, J.C. Soria, Y.W. Park, H.J. Kim, S.H. Kim, J.Y. Ro, F. Andre and S.J. Jang, Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC, Eur J Cancer 41 (2005), 2112-2119.
110. F. de Fraipont, D. Moro-Sibilot, S. Michelland, E. Brambilla, C. Brambilla and M.C. Favrot, Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer? Lung Cancer 50 (2005), 199-209.
111. S. Modi, A. Kubo, H. Oie, A.B. Coxon, A. Rehmatulla and F.J. Kaye, Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer, Oncogene 19 (2000), 4632-4639.
112. Y. Kurasono, T. Ito, Y. Kameda, N. Nakamura and H. Kitamura, Expression of cyclin D1, retinoblastoma gene protein, and p16 MTS1 protein in atypical adenomatous hyperplasia and adenocarcinoma of the lung. An immunohistochemical analysis, Virchows Arch 432 (1998), 207-215.
113. K. Kashiwabara, T. Oyama, T. Sano, T. Fukuda and T. Nakajima, correlation between the methylation status of the p16/CDKN2A gene and the expression of the p16 and Rb proteins in primary non-small cell lung cancer, Int. J. Cancer 79 (1998), 215-220.
114. H. Tanaka, Y. Fujii, H. Hirabayashi, S. Miyoshi, M. Sakaguchi, H.-E. Yoon and H. Matsuda, Disruption of the RB pathway and cell-proliferative activity in non-small cell lung cancers, Int. J. Cancer 79 (1998), 111-115.
115. R. Tanaka, D. Wang, Y. Morishita, Y. Inadome, Y. Minami, T. Iijima, S. Fukai, T. Goya and M. Noguchi, Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma, Cancer 103 (2005), 608-615.
116. K. Nakanishi, T. Kawai, F. Kumaki, S. Hiroi, M. Mukai and E. Ikeda, Survivin expression in atypical adenomatous hyperplasia of the lung, Am. J. Pathol. 120 (2003), 712-719.
117. H. Hayashi, T. Ito, T. Yazawa, M. Ikeda, Y. Inayama, Y. Nakatani, Y. Kameda, N. Nakamura and H. Kitamura, Reduced expression of p27/Kip1 is associated with the development of pulmonary adenocarcinoma, J. Pathol. 192 (2000), 26-31.
118. M. Tominaga, N. Sueoka, K. Irie, K. Iwanaga, O. Tokunaga, S. Hayashi, K. Nakachi and E. Sueoka, Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hnRNP B1 combined with the cell cyclerelated markers p16, cyclin D1, and Ki-67, Lung Cancer 40 (2003), 45-53.
119. S. Kitaguchi, Y. Takeshima, T. Nishisaka and K. Inai, Proliferative activity, p53 expression and loss of heterozygosity on 3p, 9p and 17p in atypical adenomatous hyperplasia of the lung, Hiroshima J Med Sci 47 (1998), 17-25.
120. M. Yamasaki, Y. Takeshima, S. Fujii, S. Kitaguchi, M. Matsuura, K. Tagawa and K. Inai, Correlation between genetic alterations and histopathological subtypes in bronchioloalveolar carcinoma and atypical adenomatous hyperplasia of the lung, Pathol Int 50 (2000), 778-785.
121. K. Takamochi, T. Ogura, K. Suzuki, H. Kawasaki, Y. Kurashima, T. Yokose, A. Ochiai, K. Nagai, Y. Nishiwaki and H. Esumi, Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung, Am J Pathol 159 (2001), 1941-1948.
122. H. Kohno, K. Hiroshima, T. Toyozaki, T. Fujisawa and H. Ohwada, p53 mutation and allelic loss of chromosome 3p, 9p of preneoplastic lesions in patients with nonsmall cell lung carcinoma, Cancer 85 (1999), 341-347.
123. A. Marchetti, S. Pellegrini, G. Bertacca, F. Buttitta, P. Gaeta, V. Carnicelli, V. Nardini, P. Griseri, A. Chella, C.A. Angeletti and G. Bevilacqua, FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations, J Pathol 184 (1998), 240-246.
124. K.M. Kerr, S.J. MacKenzie, S. Ramasami, G.I. Murray, N. Fyfe, A.D. Chapman, M.C. Nicolson and G. King, Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma., J. Pathol. 203 (2004), 638-644.
125. M. van Slegtenhorst, R. de Hoogt, C. Hermans, M. Nellist, B. Janssen, S. Verhoef, D. Lindhout, A. van den Ouweland, D. Halley, J. Young, M. Burley, S. Jeremiah, K. Woodward, J. Nahmias, M. Fox, R. Ekong, J. Osborne, J. Wolfe, S. Povey, R.G. Snell, J.P. Cheadle, A.C. Jones, M. Tachataki, D. Ravine, J.R. Sampson, M.P. Reeve, P. Richardson, F. Wilmer, C. Munro, T.L. Hawkins, T. Sepp, J.B. Ali, S. Ward, A.J. Green, J.R. Yates, J. Kwiatkowska, E.P. Henske, M.P. Short, J.H. Haines, S. Jozwiak and D.J. Kwiatkowski, Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34, Science 277 (1997), 805-808.
126. T.E.C.T.S. Consortium, Identification and characterization of the tuberous sclerosis gene on chromosome 16. The European Chromosome 16 Tuberous Sclerosis Consortium, Cell 75 (1993), 1305-1315.
127. K. Suzuki, T. Ogura, T. Yokose, K. Nagai, K. Mukai, T. Kodama, Y. Nishiwaki and H. Esumi, Loss of heterozygosity in the tuberous sclerosis gene associated regions in adenocarcinoma of the lung accompanied by multiple atypical adenomatous hyperplasia, Int J Cancer 79 (1998), 384-389.
128. K. Takamochi, T. Ogura, T. Yokose, A. Ochiai, K. Nagai, Y. Nishiwaki, K. Suzuki and H. Esumi, Molecular analysis of the TSC1 gene in adenocarcinoma of the lung, Lung Cancer 46 (2004), 271-281.
129. W.G. Jiang, J. Sampson, T.A. Martin, L. Lee-Jones, G. Watkins, A. Douglas-Jones, K. Mokbel and R.E. Mansel, Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes, Eur J Cancer 41 (2005), 1628-1636.
130. M. Sanchez-Cespedes, P. Parrella, M. Esteller, S. Nomoto, B. Trink, J.M. Engles, W.H. Westra, J.G. Herman and D. Sidransky, Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung, Cancer Res. 62 (2002), 3659-3662.
131. H. Ghaffar, F. Sahin, M. Sanchez-Cepedes, G.H. Su, M. Zahurak, D. Sidransky and W.H. Westra, LKB1 protein expression in the evolution of glandular neoplasia of the lung, Clin Cancer Res. 9 (2003), 2998-3003.
132. P. Fernandez, J. Carretero, P.P. Medina, A.I. Jimenez, S. Rodriguez-Perales, M.F. Paz, J.C. Cigudosa, M. Esteller, L. Lombardia, M. Morente, L. Sanchez-Verde, T. Sotelo and M. Sanchez-Cespedes, Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations, Oncogene 23 (2004), 5084-5091.
133. N. Seki, T. Takasu, K. Mandai, M. Nakata, H. Saeki, Y. Heike, I. Takata, Y. Segawa, T. Hanafusa and E. K., Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung, Clin. Cancer Res. 8 (2002), 3046-3053.
134. C.A. Eads, K.D. Danenberg, K. Kawakami, L.B. Saltz, C. Blake, D. Shibata, P.V. Danenberg and P.W. Laird, Methy-Light: a high-throughput assay to measure DNA methylation, Nucleic Acids Res. 28 (2000), E32.
135. W.B. Coleman and A.G. Rivenbark, Quantitative DNA methylation analysis: the promise of high-throughput epigenomic diagnostic testing in human neoplastic disease, J Mol Diagn 8 (2006), 152-156.
136. S. Rodenhuis and R.J. Slebos, The ras oncogenes in human lung cancer, Am Rev Respir Dis 142 (1990), S27-S30.
137. S. Rodenhuis and R.J. Slebos, Clinical significance of ras oncogene activation in human lung cancer, Cancer Res. 52 (1992), 2665s-2669s.
138. H. Shigematsu and A.F. Gazdar, Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers, Int J Cancer 118 (2006), 257-262.
139. C.A. Cooper, F.A. Carby, V.J. Bubb, D. Lamb, K.M. Kerr and A.H. Wyllie, The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung, J Pathol 181 (1997), 401-404.
140. S. Toyooka, M. Tokumo, H. Shigematsu, K. Matsuo, H. Asano, K. Tomii, S. Ichihara, M. Suzuki, M. Aoe, H. Date, A.F. Gazdar and N. Shimizu, Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers, Cancer Res. 66 (2006), 1371-1375.
141. Y. Yatabe, T. Kosaka, T. Takahashi and T. Mitsudomi, EGFR mutation is specific for terminal respiratory unit type adenocarcinoma, Am J Surg Pathol 29 (2005), 633-639.
142. Y. Yoshida, T. Shibata, A. Kokubu, K. Tsuta, Y. Matsuno, Y. Kanai, H. Asamura, R. Tsuchiya and S. Hirohashi, Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung, Lung Cancer 50 (2005), 1-8.
143. J.O. Lee, A.A. Russo and N.P. Pavletich, Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7, Nature 391 (1998), 859-865.
144. A. Destro, P. Bianchi, M. Alloisio, L. Laghi, S. Di Gioia, A. Malesci, U. Cariboni, G. Gribaudi, G. Bulfamante, A. Marchetti, S. Bosari, M. Infante, G. Ravasi and M. Roncalli, K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers, Lung Cancer 44 (2004), 23-32.
145. K.K. Divine, L.C. Pulling, P.G. Marron-Terada, K.C. Liechty, T. Kang, A.G. Schwartz, T.J. Bocklage, T.A. Coons, F.D. Gilliland and S.A. Belinsky, Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers, Int J Cancer 114 (2005), 400-405.
146. L.C. Pulling, K.K. Divine, D.M. Klinge, F.D. Gilliland, T. Kang, A.G. Schwartz, T.J. Bocklage and S.A. Belinsky, Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression, Cancer Res. 63 (2003), 4842-4848.
147. A. Shimada, J. Kano, T. Ishiyama, C. Okubo, T. Iijima, Y. Morishita, Y. Minami, Y. Inadome, Y. Shu, S. Sugita, T. Takeuchi and M. Noguchi, Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development, Cancer Sci. 96 (2005), 668-675.
148. Y. Shu, T. Iijima, W. Sun, J. Kano, T. Ishiyama, C. Okubo, Y. Anami, R. Tanaka, S. Fukai and M. Noguchi, The ACIN1 gene is hypermethylated in early stage lung adenocarcinoma, J. Thor. Oncol. 1 (2006), 160-167.
149. T.V. Colby, Wistuba, II and A. Gazdar, Precursors to pulmonary neoplasia, Adv Anat Pathol 5 (1998), 205-215.
150. H. Awaya, Y. Takeshima, V.J. Amatya, H. Ishida, M. Yamasaki, N. Kohno and K. Inai, Loss of expression of Ecadherin and beta-catenin is associated with progression of pulmonary adenocarcinoma, Pathol Int 55 (2005), 14-18.
151. N. Kanomata, R. Nakahara, T. Oda, Y. Aoyagi, G. Ishii, T. Yokose, T. Hasebe, K. Nagai, H. Yokozaki and A. Ochiai, Expression and localization of mRNAs for matrix metalloproteinases and their inhibitors in mixed bronchioloalveolar carcinomas with invasive components, Mod Pathol 18 (2005), 828-837.
152. K. Nakanishi, T. Kawai, F. Kumaki, S. Hiroi, M. Mukai, E. Ikeda, C.E. Koering and E. Gilson, Expression of mRNAs for telomeric repeat binding factor (TRF)-1 and TRF2 in atypical adenomatous hyperplasia and adenocarcinoma of the lung, Clin. Cancer Res. 9 (2003), 1105-1111.
153. T. Yoshikawal, Y. Aoyagi, K. Kodama, T. Kamijo, H. Yonou, T. Yokose, G. Ishii, T. Oda, K. Takamochi, K. Nagai, Y. Nishiwaki, N. Shimizu and A. Ochiai, Topographical distribution of allelic loss in individual lung adenocarcinomas with lymph node metastases, Mod Pathol 17 (2004), 204-213.
154. Y. Aoyagi, T. Yokose, Y. Minami, A. Ochiai, T. Iijima, Y. Morishita, T. Oda, K. Fukao and M. Noguchi, Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma, Cancer Res. 61 (2001), 7950-7954.
155. H. Awaya, Y. Takeshima, V.J. Amatya, O. Furonaka, K. Tagawa, N. Kohno and K. Inai, Inactivation of the p16 gene by hypermethylation and loss of heterozygosity in adenocarcinoma of the lung, Pathol Int 54 (2004), 486-489.
156. K.M. Kerr, F.A. Carey, G. King and D. Lamb, Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53, and c-erbB-2 expression, J Pathol 174 (1994), 249-256.
157. H. Shigematsu, T. Takahashi, M. Nomura, K. Majmudar, M. Suzuki, H. Lee, Wistuba, II, K.M. Fong, S. Toyooka, N. Shimizu, T. Fujisawa, J.D. Minna and A.F. Gazdar, Somatic mutations of the HER2 kinase domain in lung adenocarcinomas, Cancer Res. 65 (2005), 1642-1646.
158. O. Furonaka, Y. Takeshima, H. Awaya, K. Kushitani, N. Kohno and K. Inai, Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma, Pathol Int 55 (2005), 303-309.
159. M.J. Fazzari and J.M. Greally, Epigenomics: beyond CpG islands, Nat Rev Genet 5 (2004), 446-455.
160. R.M. Brena, T.H. Huang and C. Plass, Quantitative assessment of DNA methylation: potential applications for disease diagnosis, classification, and prognosis in clinical settings, J Mol Med 84 (2006), 365-377.
161. L.A. Shevde and D.R. Welch, Metastasis suppressor pathways - an evolving paradigm, Cancer Lett. 198 (2003), 1-20.
162. J.C. Berger, D. Vander Griend, W.M. Stadler and C. Rinker-Schaeffer, Metastasis suppressor genes: signal transduction, cross-talk, and the potential for modulating the behavior of metastatic cells, Anti-Cancer Drugs 15 (2004), 559-568.
163. A.M. Marchevsky, J.-H. Qiao, S. Krajisnik, J.M. Mirocha and R.J. McKenna, The prognostic significance of intranodal isolated tumor cells and micrometastases in patients with non-small cell carcinoma of the lung, J. Thorac. Cardiovasc. Surg. 126 (2003), 551-557.
164. P. Kogerman, M.S. Sy and L.A. Culp, Counter-selection for over-expressed human CD44s in primary tumors versus lung metastases in a mouse fibrosarcoma model, Oncogene 15 (1997), 1407-1416.
165. J.S. Nam, Y. Ino, Y. Kanai, M. Sakamoto and S. Hirohashi, 5-aza-2′-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis, Clin Exp Metastasis 21 (2004), 49-56.
166. J.R. Graff, E. Gabrielson, H. Fujii, S.B. Baylin and J.G. Herman, Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression, J Biol Chem 275 (2000), 2727-2732.
167. P. Gonzalez-Gomez, M.J. Bello, M.E. Alonso, C. Aminoso, I. Lopez-Marin, J.M. De Campos, A. Isla, M. Gutierrez and J.A. Rey, Promoter methylation status of multiple genes in brain metastases of solid tumors, Int J Mol Med 13 (2004), 93-98.
168. T. Kashima, K. Nakamura, J. Kawaguchi, M. Takanashi, T. Ishida, H. Aburatani, A. Kudo, M. Fukayama and A.E. Grigoriadis, Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo, Int J Cancer 104 (2003), 147-154.
169. S. Gamou, Y. Shimasato, G.T. Merlino and N. Shimizu, Methylation status of epidermal growth factor receptor gene in lung carcinoma cells, Jpn. J. Cancer Res. 79 (1988), 989-995.
170. E.J. Ormerod, C.A. Everett and I.R. Hart, Enhanced experimental metastatic capacity of a human tumor line following treatment with 5-azacytidine, Cancer Res. 46 (1986), 884-890.
171. L. Olsson and J. Forchhammer, Induction of the metastatic phenotype in a mouse tumor model by 5-azacytidine, and characterization of an antigen associated with metastatic activity, Proc Natl Acad Sci USA 81 (1984), 3389-3393.
172. H. Liu, W. Liu, Y. Wu, Y. Zhou, R. Xue, C. Luo, L. Wang, W. Zhao, J.D. Jiang and J. Liu, Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers, Cancer Res. 65 (2005), 7635-7643.
173. N.J. Belshaw, G.O. Elliott, E.A. Williams, D.M. Bradburn, S.J. Mills, J.C. Mathers and I.T. Johnson, Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer, Cancer Epidemiol Biomarkers Prev 13 (2004), 1495-1501.
174. D.R. Yates, I. Rehman, M. Meuth, S.S. Cross, F.C. Hamdy and J.W. Catto, Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls, Oncogene 25 (2006), 1984-1988.
175. A. Olek, J. Oswald and J. Walter, A modified and improved method for bisulphite based cytosine methylation analysis, Nucleic Acids Res. 24 (1996), 5064-5066.
176. J.K. Gohagan, P.M. Marcus, R.M. Fagerstrom, P.F. Pinsky, B.S. Kramer, P.C. Prorok, S. Ascher, W. Bailey, B. Brewer, T. Church, D. Engelhard, M. Ford, M. Fouad, M. Freedman, E. Gelmann, D. Gierada, W. Hocking, S. Inampudi, B. Irons, C.C. Johnson, A. Jones, G. Kucera, P. Kvale, K. Lappe, W. Manor, A. Moore, H. Nath, S. Neff, M. Oken, M. Plunkett, H. Price, D. Reding, T. Riley, M. Schwartz, D. Spizarny, R. Yoffie and C. Zylak, Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer, Lung Cancer 47 (2005), 9-15.
177. K. Travis, Lung Cancer Screening for All? Not yet, panel says, J. Natl. Cancer Inst. 96 (2004), 900-901.
178. J.A. Crestanello, M.S. Allen, J.R. Jett, S.D. Cassivi, F.C.r. Nichols, S.J. Swensen, C. Deschamps and P.C. Pairolero, Thoracic surgical operations in patients enrolled in a computed tomographic screening trial, J. Thorac. Cardiovasc. Surg. 128 (2004), 254-259.
179. S.J. Swensen, T.E. Hartman, D.E. Midthun, J.A. Sloan, A.M. Sykes, G.L. Aughenbaugh GL and M.A Clemens, Lung cancer screening with CT: Mayo Clinic experience, Radiology 226 (2003), 756-761.
180. Y. Ohde, K. Nagai, J. Yoshida, M. Nishimura, K. Takahashi, K. Suzuki, K. Takamochi, T. Yokose and Y. Nishiwaki, The proportion of consolidation to ground-glass opacity on high resolution CT is a good predictor for distinguishing the population of non-invasive peripheral adenocarcinoma, Lung Cancer 42 (2003), 303-310.
181. S.A. Ahrendt, J.T. Chow, L.H. Xu, S.C. Yang, C.F. Eisenberger, M. Esteller, J.G. Herman, L. Wu, P.A. Decker, J. Jen and D. Sidransky, Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer, J. Natl. Cancer Inst. 91 (1999), 333-339.
182. M. Esteller, M. Sanchez-Cespedes, R. Rosell, D. Sidransky, S.B. Baylin and J.G. Herman, Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients, Cancer Res. 59 (1999), 67-70.
183. S.A. Leon, B. Shapiro, D.M. Sklaroff and M.J. Yaros, Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res. 37 (1977), 646-650.
184. H. Usadel, J. Brabender, K.D. Danenberg, C. Jeronimo, S. Harden, J. Engles, P.V. Danenberg, S. Yang and D. Sidransky, Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer, Cancer Res. 62 (2002), 371-375.
185. M. Pellise, A. Castells, A. Gines, R. Agrelo, M. Sole, S. Castellvi-Bel, G. Fernandez-Esparrach, J. Llach, M. Esteller, J.M. Bordas and J.M. Pique, Detection of lymph node micrometastases by gene promoter hypermethylation in samples obtained by endosonography-guided fine needle aspiration biopsy, Clin. Cancer Res. 10 (2004), 4444-4449.
186. C. Konaka, N. Ikeda, T. Hiyoshi, K. Tsuji, T. Hirano, N. Kawate, Y. Ebihara and H. Kato, Peripheral non-small cell lung cancers 2.0 cm or less in diameter: proposed criteria for limited pulmonary resection based upon clinicopathological presentation, Lung Cancer 21 (1998), 185-191.
187. T. Koike, M. Terashima, T. Takizawa, T. Watanabe, Y. Kurita and A. Yokoyama, Clinical analysis of small-sized peripheral lung cancer, J Thorac Cardiovasc Surg 115 (1998), 1015-1020.
188. T. Takizawa, M. Terashima, T. Koike, T. Watanabe, Y. Kurita, A. Yokoyama and K. Honma, Lymph node metastasis in small peripheral adenocarcinoma of the lung, J Thorac Cardiovasc Surg 116 (1998), 276-280.
189. H. Matsuguma, R. Nakahara, M. Anraku, T. Kondo, Y. Tsuura, Y. Kamiyama, K. Mori and K. Yokoi, Objective definition and measurement method of ground-glass opacity for planning limited resection in patients with clinical stage IA adenocarcinoma of the lung, Eur J Cardiothorac Surg 25 (2004), 1102-1106.
190. H. Asamura, H. Nakayama, H. Kondo, R. Tsuchiya, Y. Shimosato and T. Naruke, Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg 111 (1996), 1125-1134.
191. J.R. Dunn, D. Panutsopulos, M.W. Shaw, J. Heighway, R. Dormer, E.N. Salmo, S.G. Watson, J.K. Field and T. Liloglou, METH-2 silencing and promoter hypermethylation in NSCLC, Br J Cancer 91 (2004), 1149-1154.
192. J. Brabender, H. Usadel, K.D. Danenberg, R. Metzger, P.M. Schneider, R.V. Lord, K. Wickramasinghe, C.E. Lum, J. Park, D. Salonga, J. Singer, D. Sidransky, A.H. Holscher, S.J. Meltzer and P.V. Danenberg, Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival, Oncogene 20 (2001), 3528-3532.
193. N. Yanagawa, G. Tamura, H. Oizumi, N. Takahashi, Y. Shimazaki and T. Motoyama, Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers, Cancer Sci. 94 (2003), 589-592.
194. A.K. Virmani, A. Rathi, U.G. Sathyanarayana, A. Padar, C.X. Huang, H.T. Cunningham, A.J. Farinas, S. Milchgrub, D.M. Euhus, M. Gilcrease, J.G. Herman, J.D. Minna and A.F. Gazdar, Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter 1A in breast and lung carcinomas, Clin. Cancer Res. 7 (2001), 1998-2004.
195. O. Topaloglu, M.O. Hoque, Y. Tokumaru, J. Lee, E. Ratovitski, D. Sidransky and C.S. Moon, Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer, Clin. Cancer Res. 10 (2004), 2284-2288.
196. A. Virmani, A. Rathi, S. Heda, K. Sugio, C. Lewis, V. Tonk, T. Takahashi, J.A. Roth, J.D. Minna, D.M. Euhus and A.F. Gazdar, Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers, Int J Cancer 107 (2003), 341-345.
197. S. Nakata, K. Sugio, H. Uramoto, T. Oyama, T. Hanagiri, M. Morita and K. Yasumoto, The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance, Cancer 106 (2006), 2190-2199.
198. S. Zochbauer-Muller, K.M. Fong, A.K. Virmani, J. Geradts, A.F. Gazdar and J.D. Minna, Aberrant promoter methylation of multiple genes in non-small cell lung cancers, Cancer Res. 61 (2001), 249-255.
199. J.S. Kim, J. Han, Y.M. Shim, J. Park and D.H. Kim, Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma, Cancer 104 (2005), 1825-1833.
200. H. Kim, Y.M. Kwon, J.S. Kim, H. Lee, J.H. Park, Y.M. Shim, J. Han, P. J. and D.H. Kim, Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer, J. Clin. Oncol. 22 (2004), 2363-2370.
201. T. Kobatake, M. Yano, S. Toyooka, K. Tsukuda, H. Dote, T. Kikuchi, M. Toyota, M. Ouchida, M. Aoe, H. Date, H.I. Pass, H. Doihara and N. Shimizu, Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas, Oncol Rep 12 (2004), 1087-1092.
202. S. Toyooka, M. Suzuki, R. Maruyama, K.O. Toyooka, K. Tsukuda, Y. Fukuyama, T. Lizasa, M. Aoe, H. Date, T. Fujisawa, N. Shimizu and A.F. Gazdar, The relationship between aberrant methylation and survival in non-small cell lung cancers, Br. J. Cancer Res. 91 (2004), 771-774.
203. T. Hanabata, K. Tsukuda, S. Toyooka, M. Yano, M. Aoe, I. Nagahiro, Y. Sano, H. Date and N. Shimizu, DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers, Oncol Rep 12 (2004), 177-180.
204. R. Cirincione, C. Lintas, D. Conte, L. Mariani, L. Roz, A.M. Vignola, U. Pastorino and G. Sozzi, Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study, Int J Cancer 118 (2006), 1248-1253.
205. A. Lamy, R. Sesboue, J. Bourguignon, B. Dautreaux, J. Metayer, T. Frebourg and L. Thiberville, Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: a prospective study in highrisk patients without invasive cancer, Int J Cancer 100 (2002), 189-193.
206. M. Seike, A. Gemma, Y. Hosoya, S. Hemmi, Y. Taniguchi, S. Fukuda, N. Yamanaka and S. Kudoh, Increase in the frequency of p16INK4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53, Clin. Cancer Res. 6 (2000), 4307-4313.
207. P.G. Corn, M.K. Summers, F. Fogt, A.K. Virmani, A.F. Gazdar, T.D. Halazonetis and W.S. El-Deiry, Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer, Carcinogenesis 24 (2003), 47-51.
208. M. Yano, S. Toyooka, K. Tsukuda, H. Dote, M. Ouchida, T. Hanabata, M. Aoe, H. Date, A.F. Gazdar and N. Shimizu, Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers, Int J Cancer 113 (2005), 59-66.
209. S. Toyooka, K.O. Toyooka, K. Miyajima, J.L. Reddy, M. Toyota, U.G. Sathyanarayana, A. Padar, M.S. Tockman, S. Lam, N. Shivapurkar and A.F. Gazdar, Epigenetic downregulation of death-associated protein kinase in lung cancers, Clin Cancer Res. 9 (2003), 3034-3041.
210. L.C. Pulling, B.R. Vuillemenot, J.A. Hutt, T.R. Devereux and S.A. Belinsky, Aberrant promoter hypermethylation of the death-associated protein kinase gene is early and frequent in murine lung tumors induced by cigarette smoke and tobacco carcinogens, Cancer Res. 64 (2004), 3844-3848.
211. D.-H. Kim, H.H. Nelson, J.K. Wiencke, D.C. Christiani, J.C. Wain, E.J. Mark and K.T. Kelsey, Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer, Oncogene 20 (2001), 1765-1770.
212. X. Tang, F.R. Khuri, J.J. Lee, B.L. Kemp, D. Liu, W.K. Hong and L. Mao, Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small cell lung cancer., J. Natl. Cancer Inst. 92 (2000), 1511-1516.
213. S. Kikuchi, D. Yamada, T. Fukami, M. Masuda, M. Sakurai-Yageta, Y.N. Williams, T. Maruyama, H. Asamura, Y. Matsuno, M. Onizuka and Y. Murakami, Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer, Clin Cancer Res. 11 (2005), 2954-2961.
214. J.C. Lai,Y.W. Cheng, H.L. Chiou, M.F. Wu, C.Y. Chen and H. Lee, Gender difference in estrogen receptor alpha promoter hypermethylation and its prognostic value in non-small cell lung cancer, Int J Cancer 117 (2005), 974-980.
215. J.P. Issa, S.B. Baylin and S.A. Belinsky, Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure, Cancer Res. 56 (1996), 3655-3658.
216. H. Chen, M. Suzuki, Y. Nakamura, M. Ohira, S. Ando, T. Iida, T. Nakajima, A. Nakagawara and H. Kimura, Aberrant methylation of FBN2 in human non-small cell lung cancer, Lung Cancer 50 (2005), 43-49.
217. D. Iliopoulos, G. Guler, S.Y. Han, D. Johnston, T. Druck, K.A. McCorkell, J. Palazzo, P.A. McCue, R. Baffa and K. Huebner, Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer, Oncogene 24 (2005), 1625-1633.
218. S. Zochbauer-Muller, K.M. Fong, A. Maitra, S. Lam, J. Geradts, R. Ashfaq, A.K. Virmani, S. Milchgrub, A.F. Gazdar and J.D. Minna, 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer, Cancer Res. 61 (2001), 3581-3585.
219. R. Maruyama, K. Sugio, I. Yoshino, Y. Maehara and A.F. Gazdar, Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma, Cancer 100 (2004), 1472-1477.
220. Y. Tomizawa, H. Iijima, T. Nomoto, Y. Iwasaki, Y. Otani, S. Tsuchiya, R. Saito, K. Dobashi, T. Nakajima and M. Mori, Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer, Lung Cancer 46 (2004), 305-312.
221. J.S. Kim, H. Kim, Y.M. Shim, J. Han, J. Park and D.H. Kim, Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung, Carcinogenesis 25 (2004), 2165-2171.
222. M. Guo, Y. Akiyama, M.G. House, C.M. Hooker, E. Heath, E. Gabrielson, S.C. Yang, Y. Han, S.B. Baylin, J.G. Herman and M.V. Brock, Hypermethylation of the GATA genes in lung cancer, Clin Cancer Res. 10 (2004), 7917-7924.
223. J.T. Chen, Y.W. Cheng, M.C. Chou, T. Sen-Lin, W.W. Lai, W.L. Ho and H. Lee, The correlation between aberrant connexin 43 mRNA expression induced by promoter methylation and nodal micrometastasis in non-small cell lung cancer, Clin Cancer Res. 9 (2003), 4200-4204.
224. K. Eguchi, Y. Kanai, K. Kobayashi and S. Hirohashi, DNA hypermethylation at the D175S locus in non-small cell lung cancers: its association with smoking history, Cancer Res. 57 (1997), 4913-4915.
225. D. Takai, Y. Yagi, K. Wakazono, N. Ohishi, Y. Morita, T. Sugimura and T. Ushijima, Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis, Oncogene 20 (2001), 7505-7513.
226. M. Shiraishi, A. Sekiguchi, A.J. Oates, M.J. Terry and Y. Miyamoto, HOXgene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas, Oncogene 21 (2002), 3659-3662.
227. G. Heller, K.M. Fong, L. Girard, S. Seidl, A. End-Pfutzenreuter, G. Lang, A.F. Gazdar, J.D. Minna, C.C. Zielinski and S. Zochbauer-Muller, Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas, Oncogene 25 (2006), 959-968.
228. U.G. Sathyanarayana, S. Toyooka, A. Padar, T. Takahashi, E. Brambilla, J.D. Minna and A.F. Gazdar, Epigenetic inactivation of laminin-5-encoding genes in lung cancers, Clin. Cancer Res. 9 (2003), 2665-2672.
229. M. Nishioka, T. Kohno, M. Tani, N. Yanaihara, Y. Tomizawa, A. Otsuka, S. Sasaki, K. Kobayashi, T. Niki, A. Maeshima, Y. Sekido, J.D. Minna, S. Sone and J. Yokota, MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer, Proc Natl Acad Sci U S A 99 (2002), 12269-12274.
230. W.A. Palmisano, K.P. Crume, M.J. Grimes, S.A. Winters, M. Toyota, M. Esteller, N. Joste, S.B. Baylin and S.A. Belinsky, Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers, Cancer Res. 63 (2003), 4620-4625.
231. S. Zochbauer-Muller, K.M. Fong, J. Geradts, X. Xu, S. Seidl, A. End-Pfutzenreuter, G. Lang, G. Heller, C.C. Zielinski, A.F. Gazdar and J.D. Minna, Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation, Oncogene 24 (2005), 6249-6255.
232. J.C. Soria, H.Y. Lee, J.I. Lee, L. Wang, J.P. Issa, B.L. Kemp, D.D. Liu, J.M. Kurie, L. Mao and F.R. Khuri, Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation, Clin Cancer Res. 8 (2002), 1178-1184.
233. C.J. Marsit, S. Zheng, K. Aldape, P.W. Hinds, H.H. Nelson, J.K. Wiencke and K.T. Kelsey, PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration, Hum Pathol 36 (2005), 768-776.
234. A. Virmani, A. Rathi, K. Sugio, U.G. Sathyanarayana, S. Toyooka, F.C. Kischel, V. Tonk, A. Padar, T. Takahashi, J.A. Roth, D.M. Euhus, J.D. Minna and A.F. Gazdar, Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer, Int J Cancer 106 (2003), 198-204.
235. A.K. Virmani, A. Rathi, S. Zochbauer-Muller, N. Sacchi, Y. Fukuyama, D. Bryant, A. Maitra, S. Heda, K.M. Fong, F. Thunnissen, J.D. Minna and A.F. Gazdar, Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas, J. Natl. Cancer Inst. 92 (2000), 1303-1307.
236. B.R. Vuillemenot, L.C. Pulling, W.A. Palmisano, J.A. Hutt and S.A. Belinsky, Carcinogen exposure differentially modulates RAR-beta promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis, Carcinogenesis 25 (2004), 623-629.
237. A. Lamy, J. Metayer, L. Thiberville, T. Frebourg and R. Sesboue, Re: Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas, J Natl Cancer Inst 93 (2001), 66-68.
238. M. Ito, G. Ito, M. Kondo, M. Uchiyama, T. Fukui, S. Mori, H. Yoshioka, Y. Ueda, K. Shimokata and Y. Sekido, Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer, Cancer Lett 225 (2005), 131-139.
239. N. Choi, D.S. Son, I. Song, H.S. Lee, Y.S. Lim, M.S. Song, D.S. Lim, J. Lee, H. Kim and J. Kim, RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer, Int J Cancer 115 (2005), 575-581.
240. D.G. Burbee, E. Forgacs, S. Zochbauer-Muller, L. Shivakumar, K. Fong, B. Gao, D. Randle, M. Kondo, A.K. Virmani, S. Bader, Y. Sekido, F. Latif, S. Milchgrub, S. Toyooka, A.F. Gazdar, M.I. Lerman, E. Zabarovsky, M. White and J.D. Minna, Epigenetic inactivation of RASFF1A in lung and breast cancers and malignant phenotype suppression, J. Natl. Cancer Inst. 93 (2001), 691-699.
241. R. Dammann, G. Yang and G.P. Pfeifer, Hypermethylation of the CpG island of Ras associated domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers, Cancer Res. 61 (2001), 3105-3109.
242. S. Honorio, A. Agathanggelou, M. Schuermann, W. Pankow, P. Viacava, E.R. Maher and F. Latif, Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients., Oncogene 22 (2003), 147-150.
243. M. Suzuki, H. Shigematsu, T. Takahashi, N. Shivapurkar, U.G. Sathyanarayana, T. Iizasa, T. Fujisawa and A.F. Gazdar, Aberrant methylation of Reprimo in lung cancer, Lung Cancer 47 (2005), 309-314.
244. K. Sato, Y. Tomizawa, H. Iijima, R. Saito, T. Ishizuka, T. Nakajima and M. Mori, Epigenetic inactivation of the RUNX3 gene in lung cancer, Oncol Rep 15 (2006), 129-135.
245. I. Krop, A. Player, A. Tablante, M. Taylor-Parker, J. Lahti-Domenici, J. Fukuoka, S.K. Batra, N. Papadopoulos, W.G. Richards, D.J. Sugarbaker, R.L. Wright, J. Shim, T.A. Stamey, W.R. Sellers, M. Loda, M. Meyerson, R. Hruban, J. Jen and K. Polyak, Frequent HIN-1 Promoter Methylation and Lack of Expression in Multiple Human Tumor Types, Mol. Cancer Res. 2 (2004), 489-494.
246. B. He, L. You, K. Uematsu, K. Zang, Z. Xu, A.Y. Lee, J.C. Costello, F. McCormick and D.M. Jablons, SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer, Proc. Natl. Acad. Sci. USA 100 (2003), 14133-14138.
247. M. Suzuki, C. Hao, T. Takahashi, H. Shigematsu, N. Shivapurkar, U.G. Sathyanarayana, T. Iizasa, T. Fujisawa, K. Hiroshima and A.F. Gazdar, Aberrant methylation of SPARC in human lung cancers, Br J Cancer 92 (2005), 942-948.
248. H.T. Zhang, X.F. Chen, M.H. Wang, J.C. Wang, Q.Y. Qi, R.M. Zhang, W.Q. Xu, Q.Y. Fei, F. Wang, Q.Q. Cheng, F. Chen, C.S. Zhu, S.H. Tao and Z. Luo, Defective expression of transforming growth factor beta receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer, Clin Cancer Res. 10 (2004), 2359-2367.
249. N. Shivapurkar, S. Toyooka, K.O. Toyooka, J. Reddy, K. Miyajima, M. Suzuki, H. Shigematsu, T. Takahashi, G. Parikh, H.I. Pass, P.M. Chaudhary and A.F. Gazdar, Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types, Int. J. Cancer 109 (2004), 786-792.
250. J. Mazieres, B. He, L. You, Z. Xu, A.Y. Lee, I. Mikami, N. Reguart, R. Rosell, F. McCormick and D.M. Jablons, Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer, Cancer Res. 64 (2004), 4717-4720.